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Jennifer L. Hall, PHDE xosomes are transport vesicles released fromcells that contain deoxyribonucleic acid,ribonucleic acid (RNA), and protein (1). Exo-
somes have captured our attention with the explosion
of diagnostics to measure the molecular proﬁles in-
side these vesicles with the purpose of detecting,
diagnosing, and treating disease.
In addition to diagnostics, therapeutic delivery
with exosomes is a topic on the minds of many. After
all, exosomes represent a proven, experienced
transportation system that provides a safe haven for
circulating small molecules with a built-in docking
system (1). If one pushes diagnostics and delivery
aside, the simple, elegant fact remains that exosomes
regulate basic daily functions, including blood coag-
ulation (2). Exosomes also orchestrate responses to
speciﬁc biological conditions, including ischemia.
Exosomes do not always contain protective contents,
nor do they always promote a protective response.
For example, exosomes are secreted by cancerous
cells that perpetuate the cancer by suppressing
immune responses. Today, many scientists and cli-
nicians are working to deﬁne the roles of exosomes in
the setting of disease.SEE PAGE 1525The study by Vicencio et al. (3) in this issue of
the Journal provides new evidence of a cardio-
protective effect of exosomes. Speciﬁcally, these
authors demonstrate compelling new data that
delivering plasma exosome fractions to rats before
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Tampa, Florida.size is reduced from w48% to 25% with delivery of
exosomes (3). The data further suggest that the exo-
somes evoked cardioprotection via a heat shock pro-
tein (HSP), known as HSP70, on the surface of the
exosome that is bound to toll-like receptor 4 (TLR4)
on recipient cells. The recipient cells were not
identiﬁed.
HSP levels are elevated after a myocardial infarc-
tion or after an ischemic event. Vicencio et al. (3)
show that HSP70 resides on the surface of the rat
and human exosomes where it binds to TLR4 on the
plasma membrane of recipient cells, leading to car-
dioprotection through extracellular signal-regulated
protein kinases 1 and 2 (ERK1/2) phosphorylation,
p38 mitogen-activated protein kinase (p38MAPK)
activation, and phosphorylation of a second HSP,
HSP27. They demonstrated that blockade of HSP70
with a neutralizing antibody prevented the car-
dioprotective effects and the ERK1/2 and p38MAPK
phosphorylation.
Vicencio et al. (3) also evaluated the delivery of an
exosome fraction to rats through the tail vein before
occlusion of the left anterior descending (LAD) artery
and showed a signiﬁcant reduction in infarct size.
A limitation of this study design was the lack of 2
controls: LAD occlusion alone and delivery of donor
rat plasma lacking exosomes. Exosomes were deliv-
ered to a cohort of rats before LAD occlusion; these
rats were then compared to a second group of rats
that received an infusion of phosphate-buffered sa-
line before the LAD occlusion (3). Including a control
with no tail vein injection before LAD would have
been helpful in the interpretation of the results (to
determine if the injections were altering the response
to the LAD occlusion).
Second, including a control where the authors
lowered the exosomes in the circulation would have
been ideal and would have served as a much stronger
control compared with the phosphate-buffered saline
used in the study. Adding a donor fraction of exo-
somes from a healthy rat, as was done, essentially
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1538doubles the amount of exosomes circulating in the
rat (since no exosomes were removed in the study
design). Thus the animals receiving phosphate-
buffered saline still have exosomes. Of note, the
Langendorff preparation used as a second series of
experiments in this study will also contain exosomes
that are released from cells in the heart that circulate
in the perfusate. Given the ﬁeld is still relatively young
at understanding the therapeutic effects of exosomes
and standardizing the “exosome fraction,” scientists
in this ﬁeld will need to push the boundaries in rigid
controls and standards for deﬁning exosome fractions.
State-of-the-art technology has allowed scientists
to deﬁne exosomes with greater precision since the
advent of their discovery more than 30 years ago.
Exosomes are considered to be 40 to 120 nm in
size (1). Markers used to deﬁne exosomes include
tetraspanins (including TSPAN29 and TSPAN30),
endosomal sorting complexes required for trans-
port (ESCRT) components, programmed cell death
6-interacting protein (PDCD6IP), tumor susceptibility
gene 101 (TSG101), ﬂotillin, and milk fat globule-
epidermal growth factor (EGF) 8 protein (MFG-E8)
(1). Cluster of differentiation (CD) 81 and CD63 have
also been used consistently in the literature to mark
exosomes andwere used in this study by Vicencio et al.
(3). Microvesicles have a much larger range in size(50 to 1000 nm) and are typically measured
with integrins, selectins, and CD40 ligand (1). Both
microvesicles and exosomes carry messenger RNA,
micro RNA, noncodingRNAs, and proteins (1). Vicencio
et al. (3) show the mean size of the particles in their
Figure 1D and they report it is around 75 nm for rats and
humans. However, in their Figure 1B (3), you can see
the particle counts in both rat and human rise above
the 120 nm particle size. Again, better standardization
and characterization of the exosomes in this studymay
have been useful.
Finally, the exosomes isolated in this study were
from healthy rats and humans. It is not clear if exo-
somes or microparticles isolated from non-healthy
rats and humans would produce the same beneﬁcial
effects.
Overall, the study from Vicencio et al. (3) raises
many new important questions for the ﬁeld while
providing evidence of cardioprotection from exo-
somes in the setting of ischemia and reperfusion.
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